Reported Saturday, Johnson & Johnson Shares New Data on RYBREVANT in Metastatic Colorectal Cancer at ESMO Congress
Reported Saturday, Johnson & Johnson Shares New Data on RYBREVANT in Metastatic Colorectal Cancer at ESMO Congress
Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT (amivantamab-vmjw) combined with chemotherapy (mFOLFOX6 [FOLFOX] or FOLFIRI) demonstrated promising rapid and durable antitumor activity in patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who have not previously received anti-epidermal growth factor receptor (EGFR) therapy. These data were presented in a mini-oral presentation at the European Society of Medical Oncology (ESMO) 2024 Congress.1
強生公司（紐交所：JNJ）今天宣佈來自第1b/2期OrigAMI-1研究的新數據，顯示RYBREVANt（amivantamab-vmjw）聯合化療（mFOLFOX6 [FOLFOX]或FOLFIRI）在之前未接受抗表皮生長因子受體（EGFR）治療的RAS/BRAF野生型（WT）轉移性結腸癌（mCRC）患者中表現出有希望的快速和持久的抗腫瘤活性。這些數據是在2024年歐洲醫學腫瘤學會（ESMO）大會上以迷你口頭報告的形式呈現的。1
譯文內容由第三人軟體翻譯。